Shugang Qin, Yuqin Teng, Jinxiu Xin, Yupei Zhang, Letao Huang, Siyu Zhao, Xiangyu Jiao, Xiaoling Yin, Shenbin Liu, Ju Sun, Weitong Xu, Yongmei Xie, Jiyan Liu, Lingxiang Kong, Xiangrong Song
The PIT strategy successfully guides the immune system to generate a broad and adaptive immunological response. This proactive, training-based paradigm offers a powerful and versatile framework for developing next-generation vaccines against highly variable pathogens.
INTRODUCTION: RNA viruses rapidly evolve to evade host immunity, posing a significant challenge to conventional vaccines. Natural infection, however, provides a blueprint for broad immunity by training the immune system against a diverse antigenic landscape. This study addresses the problem of creating a vaccine that mimics this complex training process.
OBJECTIVES: We aimed to develop and validate a novel vaccination paradigm, "Proactive Immune Training" (PIT), designed to enhance cross-reactive neutralization breadth against variants within the predicted evolutionary space.
METHODS: Using SARS-CoV-2 as a model, we constructed a 600-mutant mRNA library (m-library) based on 30 predicted high-frequency mutation sites. This library was encapsulated in proprietary lipid nanoparticles (LNPs) to form the PIT vaccine. We then evaluated a sequential prime-boost regimen consisting of a single-antigen (SA) vaccine followed by a PIT boost (SA + PIT) in BALB/c mice, assessing humoral and cellular immunity, and performing deep sequencing of B-cell and T-cell receptor repertoires.
RESULTS: The SA + PIT regimen induced significantly broader and more potent neutralizing antibodies against a range of SARS-CoV-2 variants compared to conventional regimens. This enhanced protection was mechanistically linked to a profound diversification of the T-cell and B-cell receptor repertoires, a hallmark of superior immune adaptability.
CONCLUSION: The PIT strategy successfully guides the immune system to generate a broad and adaptive immunological response. This proactive, training-based paradigm offers a powerful and versatile framework for developing next-generation vaccines against highly variable pathogens.